Longevity biotech Genflow hires Physiogenex and Accelera for MASH trials

London-listed “longevity” biotech Genflow Biosciences has added Physiogenex and Accelera to its list of CROs in deals focused on moving its gene therapy candidate into fatty acid liver disease trials.

The contracts — which Genflow described as a clinical readiness acceleration — task Physiogenex and Accelera with evaluating GF-1002, a viral vector-based gene therapy, in people with metabolic dysfunction-associated steatohepatitis (MASH).

Glenflow CEO Eric Leire said the deals reflect the growing maturity of Genflow’s pipeline and commitment to “advancing science-backed therapies in healthy aging.”

He added, “The combination of expected non-dilutive funding, strategic partnerships, and supportive regulatory tailwinds puts Genflow in a strong position to accelerate both our programs.”

The deal comes a few months after Genflow hired Exothera SA to make GF-1002 for trials. The Charleroi, Belgium-headquartered CDMO manufactures viral vectors, RNA therapeutics, and vaccines and has facilities in Belgium and the US.

Physiogenex and Accelera are just the latest contractors to be working with Genflow. In March, Bangalore, India-based contractor Syngene International began testing GF-1004, an anti-aging gene therapy designed to extend the life of canines.

Like GF-1002, the product targets a gene called SIRT6 and has the potential to slow aging and delay age-related diseases, according to Genflow.

AI analytics

News of the deals with Physiogenex and Accelera comes just a few months after Genflow teamed up with US-based, AI-driven discovery and analytics services firm Heureka Labs.

The agreement was also focused on GF-1002 with Genflow using Heureka’s AI technology to interpret biological data to gain deeper insights into regulatory networks and systemic biological responses.

At the time Leire said, “Heureka’s AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on.”

DepositPhotos/vchalup2